Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of IMM2510 plus IMM01 in advanced malignant solid tumors
CTR20253612Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM2510, timdarpacept in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), biliary cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by ImmuneOnco. Started Oct 2025; status: active.
02
Drugs
IMM2510timdarpacept
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)biliary cancergastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20253612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253612.